Latest to ride the biotech roll-er-coaster: Gilead Sciences. On May 20, it announced promising results for PMPA, a drug that combats an HIV-like virus in monkeys. Shares soared from 33 to 39. Four days later, disappointment at early findings on a genital herpes drug drove the stock to 33 3/4 on May 28. Montgomery Securities' Mark Simon says the market overreacted both times, and Gilead's outlook is hopeful.
EDITED BY KELLEY HOLLAND
Updated June 14, 1997 by bwwebmaster
Copyright 1996, Bloomberg L.P.